Posted on Thursday 27 June 2013 by Ulster Business
Local investment house Enterprise Equity sold Sepha to Cincinnati-headquartered TASI Group, a leader in the scientific inspection and test field.
The companies did not disclose the value of the deal but it is believed to have been a multi-million pound transaction.
Founded in 1980, Sepha has established a strong reputation for development of specialist machines used in the manufacture of pharmaceutical blister packs, medical device and healthcare products. With almost 100% of sales going to export markets, the company was named Exporter of the Year at this year's Aer Lingus Viscount Awards.
Sepha, which posted a 40% increase in turnover in its last financial year, said the acquisition will enable the company to build on its strong engineering and manufacturing base in East Belfast and to add further resource into its R&D centre.
New owner TASI is a manufacturer of leak test and measurement equipment used to improve quality and manufacturing efficiency in the automotive, energy, plastics, industrial, medical device and pharmaceutical markets.
Commenting on the acquisition, TASI CEO David Huberfield said: "We are very pleased to partner with Sepha in expanding our global life sciences markets and products. We are a leading global inspection and leak test provider with an expansive engineering, manufacturing and service presence on three continents and sales coverage in almost 100 countries. Sepha joins Bonfiglioli Engineering; Air Logic Power Systems [Alps]; Cincinnati Test Systems; and ATC Automation, all leaders in their field, in providing a complementary range of integrated test systems, pack inspection and instrumentation to pharmaceutical and medical device customers."
Endorsing the acquisition, Brian Cummings, director of former owners Enterprise Equity, said: "We are very pleased to hand over the reins to an ambitious global player like TASI. Sepha's success is attributed to the focus and dedication of its management team and staff in driving growth in new export markets with a diverse range of blue chip pharmaceutical clients."